Table 11. Top biological pathways overrepresented by delayed serum response miRNAs.
| KEGG pathway | FDR | Genes | miRNAs | miR-1270 | miR-139-5p | miR-30c-1-3p | miR-3664-3p | miR-3678-3p | miR-421 | miR-4529-3p | miR-4727-3p | miR-501-3p | miR-550a-3-5p | miR-5588-5p | miR-6870-3p | miR-8089 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Mucin type-O-Glycan biosynthesis | 2.9E-07 | 11 | 6 | n/a | n/a | n/a | - | n/a | + | n/a | n/a | n/a | + | - | - | - |
| Adrenergic signaling in cardiomyocytes | 2.3E-05 | 48 | 12 | - | + | + | - | - | + | - | n/a | + | + | - | - | - |
| ErbB signaling pathway | 0.0002 | 30 | 12 | - | + | + | - | - | + | - | n/a | + | + | - | - | - |
| ECM-receptor interaction | 0.0004 | 20 | 8 | - | n/a | n/a | - | - | + | n/a | n/a | + | + | n/a | - | - |
| Lysine degradation | 0.0004 | 16 | 10 | - | n/a | + | - | - | + | - | n/a | + | n/a | - | - | - |
| Axon guidance | 0.0004 | 43 | 12 | - | + | + | - | - | + | n/a | - | + | + | - | - | - |
| Proteoglycans in cancer | 0.0015 | 65 | 13 | - | + | + | - | - | + | - | - | + | + | - | - | - |
| Estrogen signaling pathway | 0.0029 | 33 | 12 | - | + | + | - | - | + | - | n/a | + | + | - | - | - |
| Glioma | 0.0047 | 22 | 11 | + | + | - | - | + | - | n/a | + | + | - | - | - | |
| Thyroid hormone synthesis | 0.0049 | 20 | 8 | - | n/a | n/a | - | - | + | - | n/a | + | + | n/a | - | - |
| Oxytocin signaling pathway | 0.0077 | 51 | 13 | - | + | + | - | - | + | - | - | + | + | - | - | - |
| TGF-beta signaling pathway | 0.0085 | 25 | 11 | - | + | + | - | - | + | - | n/a | + | + | n/a | - | - |
| Long-term potentiation | 0.0085 | 26 | 12 | - | n/a | + | - | - | + | - | - | + | + | - | - | - |
| Glutamtergic synapse | 0.0125 | 33 | 10 | - | n/a | + | - | - | + | - | n/a | + | + | n/a | - | - |
| Prostate cancer | 0.0165 | 30 | 11 | + | + | - | - | + | - | n/a | + | + | - | - | - |
Note: Conventions same as Table 8. Pathways in bold were the same or highly-related to pathways enriched in the acute saliva response miRNA targets.